// App-Quantinova.ai

484 : Long‐term safety and tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) prophylaxis: APeX‐S study results

Researchers

Presenter

  • Farkas H

Principal Investigators

  • Wu AY

  • Kiani S

  • Reshef A

  • Stobiecki M

  • Kinaciyan T

  • Maurer M

  • Aygoren-Pursun E

  • Dix D

  • Dobo S

  • Iocca H

  • Murray S

  • Sheridan WP

  • Peter J

Medical Centers

  • Semmelweis University, Budapest, Hungary

  • Center for Allergy and Asthma Care, Central, Hong Kong SAR

  • The Royal Marsden Hospital, London, United Kingdom

  • Barzilai University Hospital, Ashkelon, Israel

  • Jagiellon University Cracow, Cracow, Poland

  • Medical University of Vienna, Vienna, Austria

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Goethe University, Frankfurt, Germany

  • Dova Pharmaceuticals, Durham, United States

  • University of Cape Town, Cape Town, South Africa

Locations

  • Hungary

  • United Kingdom

  • Israel

  • Poland

  • Austria

  • Germany

  • United States

  • South Africa

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Hereditary angioedema

Biomarkers

  • N/A

Drug/Treatment

  • BCX7353

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03485911

  • NCT03472040

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved